Together, our findings suggest that TMZ has substantial activity to attenuate the progression of RA by targeting TLR4/MYD88, which consequently leads to suppression of the associated downstream TRAF6/IRAK inflammatory pathway, suggesting its therapeutic potential as an antirhomboid drug. Here, TLR4 is linked to rheumatoid arthritis.